GeneDx (NASDAQ:WGS) Announces Earnings Results, Beats Estimates By $0.66 EPS

GeneDx (NASDAQ:WGS) announced its quarterly earnings results on Tuesday. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.66, Zacks reports. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The business had revenue of $95.64 million during the quarter, compared to the consensus estimate of $82.24 million. GeneDx updated its FY 2025 guidance to EPS.

GeneDx Price Performance

NASDAQ:WGS opened at $111.31 on Thursday. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The firm has a market cap of $3.06 billion, a PE ratio of -35.79 and a beta of 2.01. GeneDx has a 12 month low of $4.61 and a 12 month high of $115.60. The company’s 50-day moving average price is $78.04 and its two-hundred day moving average price is $62.14.

Insider Transactions at GeneDx

In other GeneDx news, CEO Katherine Stueland sold 51,420 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $94.48, for a total transaction of $4,858,161.60. Following the sale, the chief executive officer now owns 1,720 shares of the company’s stock, valued at $162,505.60. This represents a 96.76 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Kevin Feeley sold 1,137 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $76.37, for a total transaction of $86,832.69. Following the transaction, the chief financial officer now owns 24,731 shares in the company, valued at $1,888,706.47. The trade was a 4.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 127,584 shares of company stock valued at $11,336,520. Corporate insiders own 27.30% of the company’s stock.

Analyst Upgrades and Downgrades

WGS has been the subject of several research analyst reports. Wells Fargo & Company upped their price target on shares of GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. The Goldman Sachs Group increased their target price on GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research note on Wednesday. Craig Hallum boosted their price objective on GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Finally, TD Cowen increased their price objective on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research note on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, GeneDx presently has an average rating of “Moderate Buy” and a consensus price target of $72.33.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.